financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Maintains Hold Opinion On Shares Of Reliance, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Maintains Hold Opinion On Shares Of Reliance, Inc.
Apr 26, 2024 1:19 PM

03:45 PM EDT, 04/26/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We decrease our 12-month target by $17 to $313, which assumes an EV/EBITDA of 10.0x our 2024 EBITDA estimate, at the upper end of the three-year range of RS's forward EV/EBITDA (4.5x-11.3x). Our DCF model shows significant upside (40%+) to RS's intrinsic value, but we are concerned about RS's relative valuation, trading at a 40% premium to peers on forward EV/EBITDA. We lower our 2024 EPS estimate by $1.44 to $19.79, but increase our 2024 EPS estimate by $1.89 to $21.08. RS posted Q1 adj. EPS of $5.30 vs. $6.37, $0.21 below consensus; Q1 revenue was down 8% Y/Y and missed consensus by 3%. During Q1, total tons sold fell 1.7% Y/Y (down 2.9% Y/Y organically) and the average selling price per ton fell 6.9% Y/Y to $2,442/ton. We anticipate a rebound in volume, with sequential growth in volume in Q2 of around 3%. We continue to be impressed with RS's resilient gross margin, which was 31.0% in Q1, up 10 basis points Y/Y. However, RS's premium valuation keeps us on the sidelines, as we see limited upside in 2024.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Keeps Hold Opinion On Shares Of Neurocrine Biosciences, Inc.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Neurocrine Biosciences, Inc.
May 26, 2025
02:05 AM EDT, 05/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price to $125 from $111, 13.8x our 2026 EPS estimate, a discount to NBIX's historical forward P/E average, justified by the concentration risk in key drug...
10 Warren Buffett dividend stocks for passive income investors
10 Warren Buffett dividend stocks for passive income investors
May 26, 2025
Dividend stocks can be a great way to generate passive income as an investor, and what better way to find dividend stock ideas than by sifting through the holdings of arguably the world's greatest investor, Warren Buffett? Berkshire Hathaway's ( BRK/A ) portfolio is filled with dividend stocks, which should come as no surprise to Buffett followers. Buffett invests in...
Is doing a VA cash-out refinance a good idea? Here's what to know
Is doing a VA cash-out refinance a good idea? Here's what to know
May 26, 2025
Key takeaways Make sure to tap into your home equity using a VA cash-out refinance for the right reasons, such as making home renovations and repairs or consolidating high-interest debt. Think twice before using a VA cash-out refinance to pay for everyday bills or big discretionary purchases like vacations, celebrations or home furnishings. While VA loans let you tap nearly...
Warren Buffett's top stock picks of all time and longest held investments
Warren Buffett's top stock picks of all time and longest held investments
May 26, 2025
Warren Buffett is one of the greatest investors of all time. Berkshire Hathaway ( BRK/A ), the company he's managed since 1965, has returned 19.9 percent annually through the end of 2024 during Buffett's leadership, nearly doubling the return of the S&P 500 on an annualized basis over that time period. A $1,000 investment in the S&P 500 would be...
Copyright 2023-2026 - www.financetom.com All Rights Reserved